Spots Global Cancer Trial Database for pomalidomide
Every month we try and update this database with for pomalidomide cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Pomalidomide-Cyclophosphamide-Dexamethasone (PCD) Versus Pomalidomide-Dexamethasone (PD) in Relapse or Refractory Myeloma | NCT03143049 | Relapse Multipl... | PCD PD | 21 Years - 99 Years | National University Hospital, Singapore | |
| Phase 1b Study Evaluating ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Dexamethasone in Relapsed or Relapsed-and-Refractory Multiple Myeloma | NCT02189343 | Multiple Myelom... | ACY-1215 in com... | 18 Years - | Celgene | |
| Pomalidomide, Dexamethasone, and Filgrastim-sndz in Treating Patients With Relapsed or Refractory Multiple Myeloma | NCT01946152 | Multiple Myelom... Recurrent Plasm... Refractory Plas... | Dexamethasone Filgrastim-sndz Laboratory Biom... Pomalidomide | 18 Years - | M.D. Anderson Cancer Center | |
| Pomalidomide or Lenalidomide and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma Previously Treated With Lenalidomide | NCT01794039 | Recurrent Plasm... Refractory Plas... | Dexamethasone Lenalidomide Pomalidomide | 18 Years - | Mayo Clinic | |
| Study of Decadron, Biaxin, and Pomalidomide in Relapsed/Refractory Myeloma | NCT01159574 | Multiple Myelom... | dexamethasone clarithromycin Pomalidomide | 18 Years - | Weill Medical College of Cornell University | |
| Immunomodulatory Drugs (Lenalidomide With or Without Pomalidomide) in Combination With a Corticosteroid Drug (Dexamethasone) for the Treatment of Multiple Myeloma | NCT05288062 | Plasma Cell Mye... Recurrent Plasm... Refractory Plas... Smoldering Plas... | Bone Marrow Bio... Dexamethasone Lenalidomide Pomalidomide | 18 Years - | Mayo Clinic | |
| Comparison of Pomalidomide and Dexamethasone With or Without Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma Previously Treated With Lenalidomide and a Proteasome InhibitorDaratumumab/Pomalidomide/Dexamethasone vs Pomalidomide/Dexamethasone | NCT03180736 | Multiple Myelom... | Daratumumab Pomalidomide Dexamethasone | 18 Years - | Stichting European Myeloma Network | |
| A Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma | NCT04722146 | Multiple Myelom... | Teclistamab Daratumumab Pomalidomide Lenalidomide Bortezomib Nirogacestat | 18 Years - | Janssen Research & Development, LLC | |
| Study to Evaluate the Safety and Efficacy of Pomalidomide Monotherapy in Subjects With Refractory or Relapsed Refractory Multiple Myeloma | NCT01324947 | Multiple Myelom... | pomalidomide | 18 Years - | Celgene | |
| A Study to Evaluate Efficacy and Safety of Alnuctamab Compared to Standard of Care Regimens in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) | NCT06232707 | Multiple Myelom... | Alnuctamab Pomalidomide Daratumumab Elotuzumab Carfilzomib Dexamethasone | 18 Years - | Celgene | |
| Study of Combination POM, BTZ, Low-Dose DEX, and DARA (PVD-DARA) in Patients With RRMM | NCT05408026 | Relapsed or Ref... | Daratumumab Pomalidomide | 18 Years - | Alliance Foundation Trials, LLC. | |
| Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Relapsed/Refractory Light Chain Amyloidosis Patients Previously Exposed to Daratumumab | NCT04270175 | Amyloid AL Amyloidosis Refractory AL A... | Daratumumab SC Pomalidomide Dexamethasone | 18 Years - | Weill Medical College of Cornell University | |
| International Treatment-extension Study in Adult Participants With Multiple Myeloma and Who Have Derived Clinical Benefit From Isatuximab | NCT05669989 | Plasma Cell Mye... | Isatuximab IV (... Cemiplimab (SAR... Dexamethasone Lenalidomide Pomalidomide Isatuximab SC (... | 18 Years - | Sanofi | |
| Efficacy and Safety of Pomalidomide in Combination With Low-dose Dexamethasone in Chinese Patients With Relapsed and Refractory Multiple Myeloma | NCT02916420 | Multiple Myelom... | Pomalidomide Dexamethasone | 18 Years - 80 Years | Jiangsu Simcere Pharmaceutical Co., Ltd. | |
| A Prospective, Non-interventional, Multinational, Observational Study With Isatuximab in Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM) | NCT04458831 | Plasma Cell Mye... | isatuximab SAR6... Pomalidomide Dexamethasone Carfilzomib | 18 Years - | Sanofi | |
| Alternate Day Dosing of Pomalidomide in Patients With Refractory Multiple Myeloma | NCT03520985 | Refractory Mult... | Pomalidomide Dexamethasone | 18 Years - | Swiss Group for Clinical Cancer Research | |
| A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomib + LDD in Triple-class Refractory MM, and Seli and Pomalidomide + LDD in Relapsed Refractory MM | NCT04414475 | Multiple Myelom... | Selinexor Dexamethasone Bortezomib Pomalidomide | 18 Years - | Karyopharm Therapeutics Inc | |
| Study of a Triple Combination Therapy, DTRM-555, in Patients With R/R CLL or R/R Non-Hodgkin's Lymphomas | NCT04305444 | Relapsed Chroni... Refractory Chro... Diffuse Large B... Follicular Lymp... Richter's Trans... | DTRM-555 | 18 Years - | Zhejiang DTRM Biopharma | |
| Study of Pomalidomide Combined With Modified DA-EPOCH and Rituximab in KSHV-Associated Lymphomas | NCT02228512 | Large Cell Lymp... Primary Effusio... | Pomalidomide Rituximab Prednisone Etoposide Doxorubicin Vincristine Cyclophosphamid... | 18 Years - 99 Years | National Institutes of Health Clinical Center (CC) | |
| Combination Study for High Risk Multiple Myeloma Patients | NCT03104270 | Multiple Myelom... | Elotuzumab Pomalidomide Carfilzomib Dexamethasone | 18 Years - | Oncotherapeutics | |
| MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide) | NCT06152575 | Multiple Myelom... | Elranatamab Elotuzumab Pomalidomide Dexamethasone Bortezomib Carfilzomib | 18 Years - | Pfizer | |
| Pomalidomide and Dexamethasone in Treating Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma or Newly Diagnosed or Relapsed or Refractory Intraocular Lymphoma | NCT01722305 | B-Cell Lymphoma... Central Nervous... Intraocular Lym... Primary Diffuse... Recurrent Adult... Retinal Lymphom... | Dexamethasone Laboratory Biom... Pharmacological... Pomalidomide | 18 Years - | Mayo Clinic | |
| IFM2009-02-Pomalidomide and Dexamethasone Phase 2 Myeloma | NCT01053949 | Multiple Myelom... | Pomalidomide Pomalidomide | 19 Years - | University Hospital, Lille | |
| Study to Evaluate CCS1477 in Haematological Malignancies | NCT04068597 | Haematological ... Acute Myeloid L... Non Hodgkin Lym... Multiple Myelom... Higher-risk Mye... Peripheral T Ce... | CCS1477 Pomalidomide Dexamethasone Azacitidine Venetoclax | 18 Years - | CellCentric Ltd. | |
| A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomib + LDD in Triple-class Refractory MM, and Seli and Pomalidomide + LDD in Relapsed Refractory MM | NCT04414475 | Multiple Myelom... | Selinexor Dexamethasone Bortezomib Pomalidomide | 18 Years - | Karyopharm Therapeutics Inc | |
| A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomib + LDD in Triple-class Refractory MM, and Seli and Pomalidomide + LDD in Relapsed Refractory MM | NCT04414475 | Multiple Myelom... | Selinexor Dexamethasone Bortezomib Pomalidomide | 18 Years - | Karyopharm Therapeutics Inc | |
| MagnetisMM-5: Study of Elranatamab (PF-06863135) Monotherapy and Elranatamab + Daratumumab Versus Daratumumab + Pomalidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma | NCT05020236 | Multiple Myelom... | Elranatamab Daratumumab Pomalidomide Dexamethasone | 18 Years - | Pfizer | |
| Efficacy and Safety of Pomalidomide and Dexamethasone in RRMM Patients With Renal Insufficiency | NCT02045017 | Multiple Myelom... | Pomalidomide an... | 18 Years - | Celgene | |
| Continuous Versus Intermittent Dosing Regimens for Pomalidomide in Relapsed/Refractory Multiple Myeloma | NCT01319422 | Multiple Myelom... | Pomalidomide | 18 Years - | Yale University | |
| Leflunomide, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma | NCT04508790 | Recurrent Plasm... Refractory Plas... | Dexamethasone Leflunomide Pomalidomide | 18 Years - | City of Hope Medical Center | |
| Study of Pomalidomide and Low Dose Dexamethasone With or Without Pembrolizumab (MK-3475) in Refractory or Relapsed and Refractory Multiple Myeloma (rrMM) (MK-3475-183/KEYNOTE-183) | NCT02576977 | Multiple Myelom... | Pembrolizumab Pomalidomide Dexamethasone | 18 Years - | Merck Sharp & Dohme LLC | |
| A Trial for Relapsed and Relapsed/Refractory Multiple Myeloma Patients | NCT04124497 | Multiple Myelom... Deletion 17P Sy... | Daratumumab Pomalidomide Dexamethasone | 18 Years - | Fondazione EMN Italy Onlus | |
| Elotuzumab, Pomalidomide, & Dexamethasone (Elo-Pom-Dex) With Second Autologous Stem Cell Transplantation for Relapsed Multiple Myeloma | NCT03030261 | Multiple Myelom... | Elotuzumab Pomalidomide Dexamethasone | 18 Years - 75 Years | Washington University School of Medicine | |
| A Study of Tazemetostat in Combination With Various Treatments in Participants With Blood Cancer. | NCT05205252 | Relapsed Hemato... Refractory Hema... | Tazemetostat Tafasitamab Lenalidomide Acalabrutinib Daratumumab (In... Mosunetuzumab Daratumumab (Su... Hyaluronidase-F... Pomalidomide Dexamethasone 2... | 18 Years - | Ipsen | |
| Pomalidomide in Treating Patients With Relapsed or Refractory Waldenstrom Macroglobulinemia | NCT01198067 | Recurrent Walde... Refractory Wald... | Pomalidomide | 18 Years - | M.D. Anderson Cancer Center | |
| Comparison of Pomalidomide and Dexamethasone With or Without Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma Previously Treated With Lenalidomide and a Proteasome InhibitorDaratumumab/Pomalidomide/Dexamethasone vs Pomalidomide/Dexamethasone | NCT03180736 | Multiple Myelom... | Daratumumab Pomalidomide Dexamethasone | 18 Years - | Stichting European Myeloma Network | |
| A Study of Selinexor, in Combination With Carfilzomib, Daratumumab or Pomalidomide in Patients With Multiple Myeloma | NCT04661137 | Multiple Myelom... | Selinexor 60 MG Selinexor 80 MG Selinexor 100 M... Carfilzomib Pomalidomide Daratumumab Dexamethasone | 18 Years - | Hackensack Meridian Health | |
| Belantamab Mafodotin, Pomalidomide and Dexamethasone for the Treatment of High-Risk Myeloma | NCT05208307 | Plasma Cell Mye... | Belantamab Mafo... Dexamethasone Pomalidomide | 18 Years - | Emory University | |
| A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide | NCT06208150 | Relapsed or Ref... | Talquetamab Pomalidomide Teclistamab Elotuzumab Dexamethasone Bortezomib | 18 Years - | Janssen Research & Development, LLC | |
| Continuous Versus Intermittent Dosing Regimens for Pomalidomide in Relapsed/Refractory Multiple Myeloma | NCT01319422 | Multiple Myelom... | Pomalidomide | 18 Years - | Yale University | |
| Selinexor, Pomalidomide, and Dexamethasone With or Without Carfilzomib for the Treatment of Patients With Relapsed Refractory Multiple Myeloma, The SCOPE Trial | NCT04764942 | Recurrent Multi... Refractory Mult... | Carfilzomib Dexamethasone Pomalidomide Quality-of-Life... Questionnaire A... Selinexor X-Ray Imaging Computed Tomogr... Positron Emissi... Bone Marrow Bio... Bone Marrow Asp... Biospecimen Col... | 18 Years - | Mayo Clinic | |
| Pomalidomide or Lenalidomide and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma Previously Treated With Lenalidomide | NCT01794039 | Recurrent Plasm... Refractory Plas... | Dexamethasone Lenalidomide Pomalidomide | 18 Years - | Mayo Clinic | |
| Ixazomib Plus Pomalidomide and Dexamethasone in Treating Patients With Relapsed or Relapsed/Refractory Multiple Myeloma | NCT02119468 | Refractory Plas... Recurrent Plasm... | ixazomib citrat... dexamethasone pomalidomide | 18 Years - | City of Hope Medical Center | |
| A Study to Determine Dose and Regimen of Durvalumab as Monotherapy or in Combination With Pomalidomide With or Without Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma | NCT02616640 | Multiple Myelom... | Durvalumab Pomalidomide Dexamethasone | 18 Years - | Celgene | |
| Pomalidomide for Myelofibrosis Patients | NCT00946270 | Polycythemia Ve... Thrombocythemia | CC-4047 Prednisone CC-4047 | 18 Years - | M.D. Anderson Cancer Center | |
| A Study to Determine the Safety and Efficacy for the Combination of Durvalumab and Daratumumab in Relapsed and Refractory Multiple Myeloma | NCT02807454 | Multiple Myelom... | Daratumumab Durvalumab Pomalidomide Dexamethasone | 18 Years - | Celgene | |
| Safety and Efficacy of Pomalidomide, Bortezomib and Low-dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma | NCT01734928 | Multiple Myelom... | Pomalidomide Bortezomib Dexamethasone | 18 Years - | Celgene | |
| Multicenter Open Label Phase 2 Study of Isatuximab Plus Pomalidomide and Dexamethasone With Carfilzomib in Relapsed or Refractory Multiple Myeloma | NCT04287855 | Multiple Myelom... Multiple Myelom... | Isatuximab Carfilzomib Pomalidomide Dexamethasone | 18 Years - | Poitiers University Hospital | |
| HDAC Inhibitor AR-42 and Pomalidomide in Treating Patients With Relapsed Multiple Myeloma | NCT02569320 | Recurrent Plasm... | Dexamethasone HDAC Inhibitor ... Laboratory Biom... Pomalidomide | 18 Years - | Ohio State University Comprehensive Cancer Center | |
| Pomalidomide in Treating Patients With Kaposi Sarcoma and Human Immunodeficiency Virus Infection | NCT03601806 | Human Immunodef... Skin Kaposi Sar... | Laboratory Biom... Pomalidomide | 18 Years - | AIDS Malignancy Consortium | |
| A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment | NCT05455320 | Relapsed or Ref... | Talquetamab Daratumumab Pomalidomide Dexamethasone | 18 Years - | Janssen Research & Development, LLC | |
| A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma | NCT06413498 | Multiple Myelom... | Anitocabtagene ... Cyclophosphamid... Fludarabine Pomalidomide Bortezomib Dexamethasone Daratumumab Carfilzomib | 18 Years - | Gilead Sciences | |
| Sequential Treatment With RO-MTX After Pomalidomide, Orelabrutinib, Rituximab (POR) in Newly-diagnosed PCNSL | NCT05390749 | Primary Central... | Orelabrutinib Pomalidomide Rituximab Methotrexate | 18 Years - 70 Years | Peking Union Medical College Hospital | |
| A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Pomalidomide in Combination With Low-Dose Dexamethasone Versus High-Dose Dexamethasone in Subjects With Refractory Multiple Myeloma or Relapsed and Refractory Multiple Myeloma and Companion Study | NCT01311687 | Multiple Myelom... | pomalidomide Dexamethasone | 18 Years - | Celgene | |
| An Efficacy Study of Pomalidomide in Patient With Multiple Myeloma in Routine Clinical Practice | NCT02902900 | Multiple Myelom... | 18 Years - | Celgene | ||
| A Safety and Efficacy Study of Carfilzomib and Pomalidomide With Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma | NCT01464034 | Multiple Myelom... | Carfilzomib Pomalidomide Dexamethasone | 18 Years - | Criterium, Inc. | |
| A Study of Belantamab Mafodotin in Combination With Nirogacestat and Pomalidomide in People With Multiple Myeloma That Has Not Responded to Treatment or Has Come Back After Treatment | NCT05556798 | Multiple Myelom... | Belantamab Mafo... Nirogacestat Pomalidomide | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM) | NCT03651128 | Multiple Myelom... | bb2121 Daratumumab Pomalidomide Dexamethasone Bortezomib Ixazomib Lenalidomide Carfilzomib Elotuzumab | 18 Years - | Celgene | |
| Pomalidomide and Dexamethasone Effects in Multiple Myeloma Patients With Del 17p or t (4;14) | NCT01745640 | Multiple Myelom... | POMALIDOMIDE Dexamethasone | 19 Years - | University Hospital, Lille | |
| Filanesib (ARRY-520) in Combination With Pomalidomide and Dexamethasone for Relapsed/Refractory (R/R) Multiple Myeloma (MM) Patients | NCT02384083 | Multiple Myelom... | Filanesib, poma... | 18 Years - | PETHEMA Foundation | |
| Study of Pomalidomide in Persons With Myeloproliferative-Neoplasm-Associated Myelofibrosis and RBC-Transfusion-Dependence | NCT01178281 | Primary Myelofi... MPN-associated ... | Pomalidomide 0.... Placebo Pomalidomide | 18 Years - | Celgene | |
| Phase I Trial of Everolimus, Pomalidomide and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma | NCT01889420 | Multiple Myelom... | Combination the... | 18 Years - | New Mexico Cancer Care Alliance | |
| A Study of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) Alone or in Combination With an Immunomodulatory Drug and/or Daratumumab in Participants With Multiple Myeloma (MM) | NCT02431208 | Multiple Myelom... | Atezolizumab (M... Daratumumab Lenalidomide Pomalidomide Dexamethasone | 18 Years - | Hoffmann-La Roche | |
| SAR650984, Pomalidomide and Dexamethasone in Combination in RRMM Patients | NCT02283775 | Plasma Cell Mye... | Isatuximab SAR6... Pomalidomide Dexamethasone | 18 Years - | Sanofi | |
| Phase 1b Study Evaluating ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Dexamethasone in Relapsed or Relapsed-and-Refractory Multiple Myeloma | NCT02189343 | Multiple Myelom... | ACY-1215 in com... | 18 Years - | Celgene | |
| A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma | NCT05572515 | Relapsed or Ref... | Teclistamab Pomalidomide Bortezomib Dexamethasone Carfilzomib | 18 Years - | Janssen Research & Development, LLC | |
| Japanese Phase 2 Study to Evaluate the Efficacy and Safety of Pomalidomide in Subjects With Relapsed and Refractory Multiple Myeloma | NCT02011113 | Multiple Myelom... | Pomalidomide Dexamethasone | 20 Years - | Celgene Corporation | |
| Pomalidomide in Combination With Liposomal Doxorubicin in People With Advanced or Refractory Kaposi Sarcoma | NCT02659930 | Kaposi Sarcoma | liposomal doxor... pomalidomide | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Japanese Phase 1 Study to Evaluate Tolerated Dose, Safety, and Efficacy of Pomalidomide in Patients With Refractory or Relapsed and Refractory Multiple Myeloma | NCT01568294 | Multiple Myelom... | pomalidomide | 20 Years - | Celgene | |
| A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment | NCT05455320 | Relapsed or Ref... | Talquetamab Daratumumab Pomalidomide Dexamethasone | 18 Years - | Janssen Research & Development, LLC | |
| Pomalidomide and Dexamethasone With or Without Ixazomib in Treating Patients With Relapsed Multiple Myeloma | NCT02004275 | Multiple Myelom... | pomalidomide ixazomib dexamethasone | 18 Years - | Alliance for Clinical Trials in Oncology | |
| A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma | NCT04910568 | Multiple Myelom... | Cevostamab Tocilizumab Pomalidomide Daratumumab Dexamethasone | 18 Years - | Genentech, Inc. | |
| Study Assessing Activity of Intravenous (IV) ABBV-383 Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma | NCT06158841 | Multiple Myelom... | ABBV-383 Carfilzomib Pomalidomide Elotuzumab Selinexor Bortezomib Dexamethasone | 18 Years - | AbbVie | |
| Daratumumab, Pomalidomide, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma | NCT03841565 | Recurrent Plasm... | Daratumumab Dexamethasone Pomalidomide | 18 Years - | Academic and Community Cancer Research United | |
| A Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma | NCT04722146 | Multiple Myelom... | Teclistamab Daratumumab Pomalidomide Lenalidomide Bortezomib Nirogacestat | 18 Years - | Janssen Research & Development, LLC | |
| A Study to Desensitize Allergic Reactions to Treatments for Blood Disorders | NCT03959358 | Multiple Myelom... Amyloidosis | Lenalidomide Pomalidomide | 18 Years - | University Health Network, Toronto | |
| Study of Pomalidomide, Cyclophosphamide, Dexamethasone in Relapsed/Refractory Multiple Myeloma | NCT02176213 | Multiple Myelom... Multiple Myelom... | Pomalidomide Cyclophosphamid... Dexamethasone | 18 Years - | Icahn School of Medicine at Mount Sinai | |
| Dose-Escalation Study of ABBV-838, an Antibody Drug Conjugate, in Subjects With Relapsed and Refractory Multiple Myeloma | NCT02462525 | Multiple Myelom... | ABBV-838 Pomalidomide Dexamethasone | 18 Years - 99 Years | AbbVie | |
| Pomalidomide in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System Tumors | NCT02415153 | Neurofibromatos... Recurrent Child... Recurrent Child... Recurrent Prima... Refractory Prim... | Laboratory Biom... Pharmacological... Pomalidomide | 3 Years - 20 Years | National Cancer Institute (NCI) | |
| Study of Belantamab Mafodotin With Carfilzomib, Pomalidomide, and Dexamethasone in Relapsed Multiple Myeloma | NCT05789303 | Multiple Myelom... Relapse Multipl... | Belantamab mafo... Carfilzomib Pomalidomide Dexamethasone | 18 Years - | University of Chicago |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
